United States · biotech/health
United States · biotech/healthDenali Therapeutics
Denali Therapeutics is dedicated to defeating neurodegenerative diseases to deliver safe and effective medicines to patients and families.
Public · FRA:4DNFor profit
Against its peers
Set against 435 biotech/health companies in United States. The ring marks the typical peer.
Across all 5.9M companies: larger than 92% of those with a size listed; older than 5% of those with a founding year; website ranked #1,551,123 in the world, about 15k visits a month.
About Denali Therapeutics
BiotechnologyGeneticsHealth DiagnosticsTherapeutics
Funding, as listed
What the source datasets report. We have not watched these rounds ourselves.
$1.1B
raised in total, currency not stated across 6 rounds
Last raised Feb 2024, 2 years ago
- Rounds
- 6
- Latest round
- Post ipo equity
- Investors
- 81 leading
Key facts
Who started it and how it trades.
- Founded by
- Alexander Schuth, Marc Lavigne, Ryan Watts
Every detail we hold
Everything the source datasets list about Denali Therapeutics, field by field. Contact details are held but never shown.
The company7 fields
- Name
- Denali Therapeutics
- Type
- For profit
- Status
- Public · FRA:4DN
- Founded
- 2013
- Founders
- Alexander Schuth, Marc Lavigne, Ryan Watts
- Industry
- biotech/health
- Categories
- Biotechnology, Genetics, Health Diagnostics, Therapeutics
Where3 fields
- City
- San Francisco
- Country
- United States
- Markets
- San Francisco Bay Area, West Coast, Western US
Size and reach3 fields
- Staff band
- 251-500
- Web traffic rank
- #1,551,123
- Monthly web visits
- 15,458
Show 10 more fieldsShow fewer fields
Funding, as listed8 fields
- Total
- 1,122,000,000 (currency not stated)
- Rounds
- 6
- Latest round
- Post ipo equity
- Latest round date
- Feb 2024
- Investors
- 8
- Lead investors
- 1
- Stock listing
- FRA:4DN
- Listing status
- public
About this record2 fields
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
Denali Therapeutics reported its fourth quarter and full year 2023 financial results, indicating a loss per share of US$0.68 in the first quarter of 2024, compared to a loss of US$0.80 in the first quarter of 2023. Despite this, Denali Therapeutics has seen a 15.6% increase in its stock price since the last earnings report.
Companies like Denali Therapeutics
biotech/health in United States.
Revolution MedicinesRedwood City · 251-500 peoplefounded 2 years later
FreenomeSouth San Francisco · 501-1000 peoplefounded 1 years later
Relay TherapeuticsCambridge · 251-500 peoplefounded 3 years later
SpringWorks TherapeuticsStamford · 251-500 peoplefounded 4 years later
Arcus BiosciencesHayward · 101-250 peoplefounded 2 years laterBuild a lead list
435 biotech/health companies in United States, filtered by size, age and reach, ready to export with emails on Pro.